Elevar's Lyrfigtu Approved for FGFR2 Cholangiocarcinoma

The FDA approved Elevar Therapeutics’ Lyrfigtu (lirafugratinib) on Sept 23 for adults with previously treated, unresectable, locally advanced or metastatic cholangiocarcinoma carrying an FGFR2 fusion or other rearrangement. The decision came two days ahead of the Sept 25 PDUFA date.

Elevar is a majority-owned subsidiary of Korea-listed HLB Co., Ltd., so it has no U.S. ticker. The stock to track is Relay Therapeutics (NASDAQ: RLAY), which invented the molecule and licensed ex-U.S. rights to Elevar for milestones and royalties. RLAY closed at $18.03 on Wednesday.

Lyrfigtu is the third drug approved for FGFR2-driven bile-duct cancer, after Incyte’s Pemazyre and Taiho’s Lytgobi, but it is the first selective FGFR2 inhibitor. The older pan-FGFR drugs trigger hyperphosphatemia and nail toxicity because they also hit FGFR1 and FGFR3. Lirafugratinib binds the ATP site of the FGFR2 receptor tyrosine kinase, and its selectivity for that single receptor is meant to spare those side effects while still shutting down the overactive signaling that drives tumor growth.

Approval rests on the single-arm Phase 1/2 ReFocus study (NCT04526106), which showed a 46% overall response rate. The addressable group is narrow: FGFR2 fusions appear in roughly 15% of intrahepatic cholangiocarcinomas, and about 8,000 Americans get a bile-duct cancer diagnosis each year.

It is also a redemption story. Elevar’s rivoceranib-camrelizumab filing for first-line liver cancer was rejected three times for its rivoceranib HCC filing, so Lyrfigtu is its first approval. For Relay, it is the first commercial product from its switch-control kinase platform, a validation even though the company handed ex-U.S. development to a partner. The full regulatory setup is in the PDUFA preview.

The win also carries broader significance for Korean biopharma. FiercePharma framed it as the first novel-drug U.S. approval for a Korean company, a proof point for HLB’s growing oncology pipeline and a potential template for other Korean developers seeking their own first U.S. nods.

The nearest risk is commercial rather than clinical. Single-arm response data does not guarantee the benefit is durable, and the two incumbent FGFR2 drugs already have prescribing momentum. Elevar needs a launch ready within days, while RLAY holders are left with milestone-and-royalty exposure rather than direct product economics.

The response durability is the open question. ReFocus is an open-label, single-arm study, so there is no randomized comparison proving Lyrfigtu extends survival versus standard chemotherapy. That gap is why launch traction matters more than the approval itself.

What to watch next: U.S. launch execution in a third-entrant market, plus Elevar’s separate European filing. The near-term update is in the launch timeline, not the clinic.

Source: Elevar Therapeutics FDA approval announcement

What It Means for the Trade

For RLAY holders, this is platform validation arriving with diluted economics. Relay invented the molecule but holds only ex-U.S.-adjacent upside through milestones and royalties — the U.S. product economics belong to Elevar. The market’s read of “first approved drug from the switch-control kinase platform” is the correct one: it proves the computational-design engine can produce a differentiated, approvable kinase inhibitor, which re-rates the rest of the pipeline more than the royalties re-rate the income statement. Treat the approval as evidence about Relay’s platform, not as a revenue event.

The differentiated pitch — fewer hyperphosphatemia and nail-toxicity events because FGFR1 and FGFR3 are spared — is exactly the kind of tolerability argument that moves community oncologists in a chronic, multi-year therapy setting like FGFR2-rearranged cholangiocarcinoma. But it has to be visible in the label’s safety section to be sellable, and it has to be priced sanely next to incumbents.

Mechanism and Market Context

FGFR2 fusions and rearrangements turn the FGFR2 receptor tyrosine kinase into a constitutively active growth driver — roughly 15% of intrahepatic cholangiocarcinomas carry one, and that biomarker-defined subset is the entire market. The incumbent drugs are pan-FGFR inhibitors: they hit the cancer driver but also FGFR1 (phosphate metabolism) and FGFR3 (nail and mucosal biology), producing the class’s signature toxicities that force dose interruptions and drop-outs. Lirafugratinib’s selectivity for FGFR2 alone is the whole thesis — cleaner targeting, fewer interruptions, longer effective treatment duration.

The 46% overall response rate in the single-arm ReFocus study is competitive with what the class has shown, though cross-trial comparisons across different FGFR2-rearranged populations are never apples-to-apples and should be treated as directional only. The durability question matters more: response rate without a randomized survival comparison leaves the value proposition resting on tolerability-driven treatment persistence, which is exactly what the launch has to demonstrate in practice.

Risks and What Could Go Wrong

1. Third-entrant share fight. Pemazyre and Lytgobi own the prescriber relationships; a two-day-early approval does not buy switching behavior. Slow uptake is the base-rate outcome for me-too-with-a-twist oncology launches.
2. Single-arm data limits. No randomized comparison means payers and guideline committees may position Lyrfigtu behind the incumbents despite the selectivity story.
3. Relay’s royalty-only exposure. Milestones can stall if Elevar under-executes the launch, and RLAY’s re-rating depends on pipeline reads, not this commercial curve.
4. Elevar execution and history. A company that drew three CRLs on a different filing is now running its first U.S. launch with days of runway from approval to commercial availability.

Sized honestly: modest optionality for RLAY, an execution test for Elevar. Not a position-building event on either side.